Authors' reply

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7023.123b (Published 13 January 1996) Cite this as: BMJ 1996;312:123
  1. R H Vander Stichele,
  2. M G Bogaert,
  3. E Dezeure
  1. General practitioner Clinical pharmacologist School health services physician Heymans Institute of Pharmacology, University of Ghent, B-9000 Ghent, Belgium

    EDITOR,—Rumona Dixon and colleagues comment on the fact that we knowingly omitted from our review 11 unpublished trials, sponsored by Well-come, comparing permethrin with malathion. We found abstracts of these trials by tracking the trail of references in advertising material. These small trials apparently showed optimal results both for the drug under investigation (permethrin, a Wellcome product) and for malathion, the comparator. As the abstracts did not permit thorough evaluation of the quality of the trials we were …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription